Deciphera Pharmaceuticals
The Director, Intellectual Property at Deciphera leads the preparation and prosecution of complex patents across chemistry, biologics, formulation, and process chemistry, collaborating with R&D scientists, engineers, executives, and external counsel. This role manages global IP strategy, portfolio oversight, and provides guidance on patent and trade secret matters while supporting the company's innovative drug development pipeline.
Headquarters
Waltham, Massachusetts, United States
Company Size
201-500 employees
Founded
2003
Deciphera Pharmaceuticals, now a member of ONO Pharma, is a biopharmaceutical company dedicated to discovering, developing, and commercializing switch-control kinase inhibitors and other targeted therapies to improve outcomes for people with cancer. The company's portfolio includes approved medicines QINLOCK (ripretinib) for advanced gastrointestinal stromal tumor and ROMVIMZA (vimseltinib), as well as a broad pipeline of clinical-stage candidates such as tirabrutinib and sapablursen. Driven by a patient-inspired mission to defeat cancer, Deciphera focuses on addressing key mechanisms of tumor and drug resistance through its proprietary discovery platform.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Deciphera Pharmaceuticals.
32% above the average for this role
Patent Agent – Life Sciences #22044 Boston
The Vanguard Group, Inc.
Patent Agent – Life Sciences #22043 Washington, DC
The Vanguard Group, Inc.
Patent Agent – Life Sciences #22045 New York
The Vanguard Group, Inc.
Patent Agent (Life Sciences) #21642 Boston
The Vanguard Group, Inc.
Senior Patent Counsel
Scripps Research
Patent Agent (Life Sciences) #21643 New York
The Vanguard Group, Inc.